Neuropsychiatric systemic lupus erythematosus: a diagnostic challenge by Sommerlad, A et al.
 Revised July 2013  Page 1 of 8 
 
TITLE OF CASE  




A 58 year old woman presented to neuropsychiatric services with increased frequency of confusional 
episodes and intermittent psychotic symptoms. She had a 19 year history of atypical epileptic seizures 
and cognitive decline. Detailed review of past history and clinical investigations revealed that she had 
accumulated sufficient features to meet diagnostic criteria for systemic lupus erythematosus (SLE); she 
had previously had lymphopenia and a malar rash and she had positive anti-nuclear, anti-Ro and anti-SM 
antibodies, and elevated erythrocyte sedimentation rate. The seizures, cognitive impairment and 
psychosis were attributable to neuropsychiatric SLE. Treatment with immune-modulating therapy, 
cyclophosphamide, resulted in significant improvement in subjective and objective clinical presentation. 
 
Neuropsychiatric SLE should be considered a potential differential diagnosis for patients presenting with 
seizures, psychotic symptoms or cognitive decline. A detailed clinical evaluation with review of the 
medical history and appropriate laboratory analyses allows this diagnosis to be made, and appropriate 
treatment to be initiated. 
BACKGROUND  
Systemic lupus erythematosus (SLE) is an autoimmune disease in which the immune system reacts 
against host antigens resulting in dysfunction in various organ systems. The symptoms are often insidious 
in onset and non-specific in nature, making diagnosis difficult. Neuropsychiatric symptoms affect up to 
90% of patients with SLE, with cognitive impairment, headache and mood disorder being the most 
commonly recognised syndromes[1]. 
 
We present the case of a 58 year old woman who was diagnosed with SLE after a 19 year history of 
epilepsy and cognitive decline and responded well to immunotherapy. 
CASE PRESENTATION  
A 58 year old female Vietnamese former primary school teacher was admitted to a neuropsychiatric 
inpatient ward following increasingly frequent episodes of confusion and disorientation. 
 
She had originally been referred to Neuropsychiatric services in 1993 when she began to develop 
prolonged episodes of confusion which were thought to be psychogenic non-epileptic seizures. An 
electroencephalogram (EEG) following an episode in an outpatient clinic indicated postictal slowing 
leading to the diagnosis of focal epilepsy. She did not experience any typical clinical features of complex 
partial seizures. 
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She was lost to follow-up for many years and was re-referred to neuropsychiatry when the confusional 
episodes became more frequent. These episodes were now associated with headache, visual illusions, 
auditory hallucinations and persecutory ideas. A prolonged period of EEG monitoring in 2006 
demonstrated runs of subclinical seizure activity, which correlated with her confusional state. Psychotic 
symptoms were considered to be related to post-ictal activity and antipsychotic medication (risperidone) 
was used to control these symptoms. Treatment also consisted of antiepileptic medication; therapeutic 
doses of a number of different medications were trialled with limited success in controlling her apparent 
seizures. 
 
In 2010, she developed a malar facial rash and left shoulder pain which resolved spontaneously. 
 
She was re-admitted to our inpatient neuropsychiatric unit in 2012 due to complaints from her family of 
worsening and increasingly frequent episodes of confusion and nocturnal enuresis which resulted in the 
need for 24 hour care. These episodes were now occurring on a daily basis. There was fluctuating 
conscious level but no overt motor seizure activity or psychotic symptoms. 
 
She had well-controlled hypertension but no other chronic medical problems, did not drink alcohol and 
was a non-smoker. There was no evidence of Raynaud’s Phenomenon. 
 
Mental state examination revealed psychomotor agitation, reduced spontaneity of speech and prolonged 
speech latency and, although she was orientated in place, she was disorientated in time and unable to 
respond appropriately to questions about recent events. There was slowing of fine motor movements 
and reduced arm swing on walking and no other neurological deficit was noted. 
 
INVESTIGATIONS  
Detailed neuropsychological assessment, with a Vietnamese interpreter, demonstrated limited non-
verbal reasoning, visual recall memory, executive function and speed of information processing, with 
relatively intact nominal and visuoperceptual skills. She had not undergone previous neuropsychological 
testing for comparison but these results suggested marked intellectual underfunctioning. 
 
Twenty four hour ambulatory EEG did not show epileptiform activity, which contrasted with EEG in 2008, 
which had demonstrated sharp wave activity arising in the left parietal region. An MRI brain scan showed 
volume loss in the left medial temporal lobe, unchanged from serial imaging over the preceding ten 
years. 
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Antinuclear antibody (ANA) was weakly positive at 1:40 and the extractable nuclear antigens (ENA), Anti-
Ro and Anti-SM, were both positive. Anti-cardiolipin antibody was positive but other antiphospholipid 
antibodies were negative. Review of her clinical notes demonstrated that her ESR had been mildly raised 
in the past and she had previously been lymphopenic. 
 
DIFFERENTIAL DIAGNOSIS  
The history indicated that she met five of the American College of Rheumatology’s (ACR) 11 clinical 
diagnostic criteria for systemic lupus erythematosus[2]: 
 
1) Malar rash 
2) Neurological disorder – psychosis and seizures 
3) Haematological disorder – lymphopenia 
4) Immunological disorder – positive ENAs, raised ESR. 
5) Antinuclear antibody – positive 
 
Clinical opinion was sought from a specialist in Neuroimmunology and it was agreed that a clinical 
diagnosis of neuropsychiatric SLE was likely. The initiation of relevant treatment was discussed in detail 
with the patient. 
TREATMENT  
Treatment with pulsed intravenous cyclophosphamide (15mg/kg, three weekly) was initiated, along with 
Mesna cover, to prevent cystitis. Due to a self-limiting episode of neutropenia after the first dose, the 
dose was reduced to 60% of its original level and continued on a three weekly basis until she had 
received three intravenous doses. Thereafter, the cyclophosphamide was converted to a three weekly 
pulsed oral cyclophosphamide regimen – seven additional treatments – which she tolerated without 
complications. Subsequently she was maintained on azathioprine 125mg daily.  
 
OUTCOME AND FOLLOW-UP   
Five months following the initiation of cyclophosphamide treatment, the patient was significantly less 
confused and demonstrated a marked improvement in social and cognitive function. She said that she 
felt better and her family described her as alert, more coherent and less drowsy. Episodes of nocturnal 
urinary incontinence resolved and she had become independent for self-care and been able to help out 
with domestic tasks. She showed an interest in puzzle games and current affairs. 
 
Mental state examination showed her affect to be more reactive and there continued to be no psychotic 
or affective symptoms. 
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Neuropsychological assessment at five months after initiation of cyclophosphamide demonstrated 
significant improvement from the previous assessment, with improved visual recall and non-verbal 
reasoning. Executive function and attention remained impaired. 
 
Antipsychotic medication was gradually withdrawn without any problems and her antiepileptic 
medication reduced to Levetiracetam 1g BD and Gabapentin 600mg TDS. She has continued taking oral 
azathioprine as maintenance immunotherapy for the past 18 months. 
 
DISCUSSION 
This case of a 58 year old Vietnamese lady with a long history of atypical seizures, intermittent psychotic 
symptoms and progressive cognitive impairment demonstrates the value of vigilance for symptoms 
which indicate the diagnosis of neuropsychiatric SLE. 
 
SLE has been described as the ‘disease with a thousand faces’[3] due to the heterogeneity of clinical 
presentation, which often makes diagnosis difficult. In this case, the diagnosis had been delayed because 
of the unusual presentation of her symptoms. She was initially referred for suspected non-epileptic 
seizures as her confusional episodes did not clinically resemble complex partial seizures, with no 
automatisms. In addition to this, the protracted illness course with gradual accumulation of symptoms 
and biomarkers required for the diagnosis of SLE, rather than coexistence of these, resulted in the 
diagnostic challenge. 
 
Revisiting the long history of the required diagnostic features allowed us to initiate a disease-modifying 
treatment for the neuropsychiatric SLE[4].  We postulate that the reduced frequency of confusional 
episodes reflecting subclinical seizures and significant improvement in cognitive function in our patient 
are attributable to the immunosuppressive effect of cyclophosphamide. 
 
SLE is a chronic, relapsing-remitting systemic disease which is characterised by loss of immune tolerance, 
autoantibody production and immune complex deposition resulting in systemic inflammation. SLE is 
approximately four times more common in people of South East Asian ethnicity than White 
Caucasians[5], with a prevalence around 40/100,000[6], and mortality in this group is higher[5]. The 
preponderance of SLE in women is well established[7]. 
 
Prevalence estimates of neuropsychiatric symptoms in SLE varies according to how symptoms are 
defined. Studies have demonstrated prevalence of all symptoms around 90%[1], but when only major 
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central nervous system (CNS) manifestations such as psychosis, myelopathy, strokes and seizures, are 
included and non-specific symptoms like headache and mild depression are excluded, prevalence falls to 
4.3%[8]. In a case series of people with SLE, presence of antiphosholipid and anti-SM and -Ro antibodies 
were predictive of neuropsychiatric disease[9]. 
 
Neuropsychiatric symptoms of SLE have been divided by the ACR into CNS manifestations including 
cerebrovascular disease, cognitive dysfunction, seizures and psychosis, and peripheral nervous system 
disorders such as autonomic disorder, myasthenia gravis and mononeuropathies[10]. Neuropsychiatric 
symptoms of SLE are associated with generalised SLE activity and often recur[11]. The incidence of 
epilepsy in SLE is three times that of the general population and people with SLE and epilepsy are more 
likely to experience psychiatric disorders[12]. However, as in this case, seizures often predate other 
symptoms by many years and so diagnosis of isolated epilepsy syndromes is common[13]. Seizures 
commonly co-occur with cerebral atrophy[14]. 
 
Cognitive dysfunction in SLE can be associated with cerebral atrophy although markers of systemic 
disease involvement are not correlated with cognitive function[15]. It is a common neuropsychiatric 
feature of SLE, occurring to a mild or moderate extent in two-thirds of cases[16], although severe 
cognitive impairment is only seen in around 5% of people with SLE[11]. Cognitive dysfunction can occur 
in the early stages of the disease process but is rare[17] and, while cognitive function can deteriorate 
throughout the disease course, it often fluctuates or improves over time[18, 19]. The profile of cognitive 
deficits seen in SLE is varied but the most frequently affected domains are attention, memory, 
visuospatial processing, language, problem solving, speed of information processing and executive 
function[10]. The presence of cerebral atrophy, as was seen in this case, increases the risk of cognitive 
impairment[17]. 
 
Diagnosis of patients presenting with symptoms of neuropsychiatric SLE is challenging. Thorough medical 
history and clinical evaluation using relevant laboratory analyses aims to exclude other potential causes 
and attribute symptoms to SLE[20]. 
 
Although there is a paucity of high quality evidence on the management of neuropsychiatric symptoms 
of SLE, recommendations have been made on the basis of the available evidence. Treatment of cognitive 
dysfunction should include appropriate management of SLE and non-SLE associated factors, such as 
depression or physical ill-health. Non-pharmacological approaches such as cognitive rehabilitation 
programmes should also be considered. While long term anti-epileptic drug therapy is usually not 
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indicated following a single seizure, recurrent SLE-related seizures should be managed using anti-
epileptic therapy. Immunotherapy should be considered in systemic disease associated with seizures[11]. 
Individual case reports have also described response of psychiatric symptoms to immunotherapy[21]. 
LEARNING POINTS/TAKE HOME MESSAGES  
 Neuropsychiatric symptoms are common in Systemic Lupus Erythematosus (SLE) but diagnosis 
can be difficult. 
 The presence of atypical refractory symptoms, such as psychosis or seizures, should prompt 
diagnostic evaluation for neuropsychiatric SLE. 
 Seizures often predate other neuropsychiatric symptoms of SLE, so vigilance for the subsequent 
emergence of other potential diagnostic criteria of SLE is important. These may not all occur at 
the same time. 
  A robust and timely diagnosis of SLE allows management of symptoms, including symptomatic 
management, treatment of associated factors and consideration of immunotherapy. 
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